Resubmit the New Drug Application for reproxalap
Delivered after the deadline (95 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Nov 2023
- Due
- 30 Jun 2024
- Delivered
- 3 Oct 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“successful results from the proposed trial are expected to allow for potential resubmission of the New Drug Application (NDA) in the first half of 2024”
What we found
Evidence strength A What the grades mean
The company committed to resubmitting the NDA in the first half of 2024, but the actual resubmission occurred in October 2024.
-
A Aldeyra Therapeutics, Inc. 10-K filed 2025-02-28
“On October 3, 2024, Aldeyra announced resubmission of the NDA (the Resubmitted NDA)” ✓ confirmed on the page
Market reaction: the shares moved -1.3% against the S&P 500 over the three sessions around the disclosure (27 Feb 2025 to 4 Mar 2025). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- Language weakened: expected → aspirational
- 3 versions
-
Version 1 · original · stated 28 Nov 2023
Deadline 30 Jun 2024 (“first half of 2024”) · wording expected
-
Version 2 · stated 28 Mar 2024
Deadline 31 Dec 2024 (“in the second half of 2024”) · wording expected
“Contingent on positive results from the planned clinical trial, NDA resubmission is expected in the second half of 2024.”
-
Version 3 · stated 3 Apr 2025
Deadline 30 Jun 2025 (“mid-year 2025”) · wording aspirational
“Subject to positive results and discussions with the FDA, Aldeyra intends to resubmit the NDA mid-year 2025.”
-
Version 4 · stated 6 May 2025
Deadline 30 Jun 2025 (“mid-2025”) · wording expected
“Pending a Type A meeting with the FDA, NDA resubmission is anticipated mid-2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Resubmit
- Deliverable
- resubmission of the New Drug Application
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: pending FDA feedback on the SPA; successful results from the proposed trial
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ALDX-003526 · Corrections policy